ZD 8321
Latest Information Update: 15 Sep 2000
Price :
$50 *
At a glance
- Originator AstraZeneca
- Class Antiasthmatics
- Mechanism of Action Leucocyte elastase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Acute lung injury; Adult respiratory distress syndrome; Bronchitis; Chronic obstructive pulmonary disease; Heart failure; Systemic inflammatory response syndrome
Most Recent Events
- 15 Sep 2000 Discontinued-II for Acute lung injury in USA (IV)
- 15 Sep 2000 Discontinued-II for Adult respiratory distress syndrome in USA (IV)
- 15 Sep 2000 Discontinued-Phase I in Bronchitis in USA (PO)